SG11201801193QA - Tetrahydrooxepinopyridine compound - Google Patents

Tetrahydrooxepinopyridine compound

Info

Publication number
SG11201801193QA
SG11201801193QA SG11201801193QA SG11201801193QA SG11201801193QA SG 11201801193Q A SG11201801193Q A SG 11201801193QA SG 11201801193Q A SG11201801193Q A SG 11201801193QA SG 11201801193Q A SG11201801193Q A SG 11201801193QA SG 11201801193Q A SG11201801193Q A SG 11201801193QA
Authority
SG
Singapore
Prior art keywords
tetrahydrooxepinopyridine
compound
tetrahydrooxepinopyridine compound
Prior art date
Application number
SG11201801193QA
Other languages
English (en)
Inventor
Yohei Koganemaru
Satoshi Miyamoto
Shinya Nagashima
Akio Kamikawa
Koichi Yonezawa
Yuka Koizumi
Satoshi Aoki
Takashi Ogiyama
Shimpei Kawakami
Shigeki Kunikawa
Ryo Sato
Junichi Shishikura
Shuichirou Kakimoto
Hiroshi Yamada
Keisuke Tamaki
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of SG11201801193QA publication Critical patent/SG11201801193QA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG11201801193QA 2015-08-19 2016-08-18 Tetrahydrooxepinopyridine compound SG11201801193QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015162320 2015-08-19
PCT/JP2016/074145 WO2017030171A1 (ja) 2015-08-19 2016-08-18 テトラヒドロオキセピノピリジン化合物

Publications (1)

Publication Number Publication Date
SG11201801193QA true SG11201801193QA (en) 2018-03-28

Family

ID=58052257

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201801193QA SG11201801193QA (en) 2015-08-19 2016-08-18 Tetrahydrooxepinopyridine compound

Country Status (21)

Country Link
US (1) US9670219B2 (he)
EP (1) EP3345909B1 (he)
JP (1) JP6787320B2 (he)
KR (1) KR102614279B1 (he)
CN (1) CN107922426B (he)
AR (1) AR105738A1 (he)
AU (1) AU2016308406A1 (he)
CA (1) CA2995554C (he)
CO (1) CO2018002472A2 (he)
EA (1) EA034794B1 (he)
ES (1) ES2812246T3 (he)
HK (1) HK1251574A1 (he)
IL (1) IL257450A (he)
MX (1) MX2018002118A (he)
PH (1) PH12018500297A1 (he)
PL (1) PL3345909T3 (he)
PT (1) PT3345909T (he)
SG (1) SG11201801193QA (he)
TW (1) TW201722962A (he)
WO (1) WO2017030171A1 (he)
ZA (1) ZA201801098B (he)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110207773A1 (en) * 2008-08-21 2011-08-25 Neurosearch A/S Novel phenyl-quinoline-carboxylic acid pyridine derivatives useful as modulators of nicotinic acetylcholine receptors
GB201106829D0 (en) 2011-04-21 2011-06-01 Proximagen Ltd Heterocyclic compounds
AU2012219537B2 (en) 2011-02-25 2016-07-28 Janssen Pharmaceutica Nv (pyridin-4-yl)benzylamides as allosteric modulators of alpha 7 nAChR
AR086791A1 (es) * 2011-07-01 2014-01-22 Lundbeck & Co As H Moduladores alostericos positivos del receptor de acetilcolina nicotinico
US20130005743A1 (en) * 2011-07-01 2013-01-03 H. Lundbeck A/S New positive allosteric modulators of nicotinic acetylcholine receptor

Also Published As

Publication number Publication date
EP3345909B1 (en) 2020-06-17
PL3345909T3 (pl) 2020-10-19
PT3345909T (pt) 2020-07-29
KR20180037983A (ko) 2018-04-13
ZA201801098B (en) 2019-04-24
IL257450A (he) 2018-04-30
KR102614279B1 (ko) 2023-12-18
EP3345909A4 (en) 2019-04-10
WO2017030171A1 (ja) 2017-02-23
PH12018500297A1 (en) 2018-08-13
AU2016308406A1 (en) 2018-03-08
CA2995554A1 (en) 2017-02-23
BR112018003171A2 (pt) 2018-09-25
US20170050973A1 (en) 2017-02-23
CN107922426A (zh) 2018-04-17
MX2018002118A (es) 2018-06-18
EP3345909A1 (en) 2018-07-11
AR105738A1 (es) 2017-11-01
CA2995554C (en) 2023-06-27
JPWO2017030171A1 (ja) 2018-06-07
CN107922426B (zh) 2021-03-26
CO2018002472A2 (es) 2018-05-31
JP6787320B2 (ja) 2020-11-18
HK1251574A1 (zh) 2019-02-01
TW201722962A (zh) 2017-07-01
ES2812246T3 (es) 2021-03-16
EA201890514A1 (ru) 2018-07-31
US9670219B2 (en) 2017-06-06
EA034794B1 (ru) 2020-03-23

Similar Documents

Publication Publication Date Title
GB201510019D0 (en) Compounds
ZA201802648B (en) Compounds
GB201514754D0 (en) Compounds
GB201514751D0 (en) Compounds
GB201508747D0 (en) Compounds
HK1255832A1 (zh) 吡喃並二吡啶化合物
GB201521524D0 (en) Compound
GB201520500D0 (en) Compounds
ZA201800733B (en) Compounds
GB201520499D0 (en) Compounds
GB201508864D0 (en) Compounds
GB201520419D0 (en) Compounds
GB201510493D0 (en) Compounds
GB201518950D0 (en) Compound
GB201508857D0 (en) Compounds
GB201503926D0 (en) Compounds
GB201501115D0 (en) Compounds
HK1251574A1 (zh) 四氫噁庚英吡啶化合物
GB201520391D0 (en) Compound
GB201520393D0 (en) Compound
GB201509303D0 (en) Compound
GB201521086D0 (en) Compounds
GB201519969D0 (en) Compounds
GB201519965D0 (en) Compounds
GB201519549D0 (en) Compounds